Gene-modified tumor vaccine with therapeutic potential shifts tumor- specific T cell response from a type 2 to a type 1 cytokine profile

Journal of Immunology

Volumn 161, Issue 6, 1998, Pages 3033-3041

  Hu, Hong Ming ^a,b   Urba, Walter J ^a,b   Fox, Bernard A ^a,b,c,d  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; TUMOR VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; IMMUNOGENICITY; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; T LYMPHOCYTE; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CANCER VACCINES; CELL SEPARATION; CYTOKINES; CYTOMEGALOVIRUS; FEMALE; GENES, MHC CLASS I; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; L-SELECTIN; LYMPH NODES; MELANOMA; MICE; MICE, INBRED C57BL; TH1 CELLS; TH2 CELLS; TUMOR CELLS, CULTURED; VACCINES, DNA;

EID: 0032530377     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Mosmann, T. R., and S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17:138.
2. Salgame, P., J. S. Abrams, C. Clayberger, H. Goldstein, J. Convit, R. L. Modlin, and B. R. Bloom. 1991. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254:279.
3. Croft, M., L. Carter, S. L. Swain, and R. W. Dutton. 1994. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J. Exp. Med 180:1715.
4. Li, L., S. Sad, D. Kagi, and T. R. Mosmann. 1997. CD8Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions. J. Immunol 158:4152.
5. + T cells. Annu. Rev. Immunol. 12:635.
6. Nakamura, T., R. K. Lee, S. Y. Nam, E. R. Podack, K. Bottomly, and R. A. Flavell. 1997. Roles of IL-4 and IFN-γ in stabilizing the T helper cell type 1 and 2 phenotype. J. Immunol 158:2648.
7. Tsung, K., J. B. Meko, G. R. Peplinski, Y. L. Tsung, and J. A. Norton. 1997. IL-12 induces T helper 1-directed antitumor response. J. Immunol. 158:3359.
8. Aruga, A., E. Aruga, K. Tanigawa, D. K. Bishop, V. K. Sondak, and A. E. Chang. 1997. Type 1 vs type 2 cytokine release by V β T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J. Immunol. 159: 664.
9. Lowes, M. A., G. A. Bishop, K. Crotty, R. S. Barnetson, and G. M. H. 1997. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J. Invest. Dermatol. 108:914.
10. Zitvogel, L., J. Mayordomo, T. Tjandrawan, A. DeLeo, M. Clarke, M. Lotze, and W. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87.
11. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
12. Mobley, J., and M. Dailey. 1992. Regulation of adhesion molecule expression by CD8 T cells in vivo. I. Differential regulation of gp90 MEL-14 (LECAM-1), Pgp-1, LFA-1, and VLA-4α during the differentiation of cytotoxic T lymphocytes induced by allografts. J. Immunol. 148:2348.
13. Mobley, J., S. Rigby, and M. Dailey. 1994. Regulation of adhesion molecule expression by CD8 T cells in vivo. J. Immunol. 153:5443.
14. + T cells in lymph node and lung of mice with sendai virus pneumonia by LECAM-1 and CD45RB phenotype. J. Immunol. 150:5494.
15. Andersson, E., J. Christensen, O. Marker, and A. A. Thomsen. 1994. Changes in cell adhesion molecule expression on T cells associated with systemic virus infection. J. Immunol 152:1237.
16. - helper cells that secretes interleukin 2 (IL-2), IL-3, IL-4, and interferon gamma. J. Exp. Med. 174:547.
17. Blanckaert, V. D., M. E. Schelling, C. A. Elstad, and G. G. Meadows. 1993. Differential growth factor production, secretion, and response by high and low metastatic variants of B16BL6 melanoma. Cancer Res. 53:4075.
18. Thompson, T. C., L. D. Truong, T. L. Timme, D. Kadmon, B. K. McCune, K. C. Flanders, P. T. Scardino, and S. H. Park. 1993. Transgenic models for the study of prostate cancer. Cancer 71:1165.
19. Corny, R. M., A. F. LoBuglio, F. Loechel, S. E. Moore, L. A. Sumerel, D. L. Barlow, and D. T. Curiel. 1994. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther. 1:1.
20. Yoshizawa, H., K. Sakai, A. E. Chang, and S. Shu. 1991. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell Immunol. 134:473.
21. Yoshizawa, H., A. E. Chang, and S. Shu. 1991. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol. 147:729.
22. Kagamu, H., J. Touhalisky, G. Plautz, J. Krauss, and S. Shu. 1996. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res. 56:4338.
23. + tumor-infiltrating lymphocytes. J. Exp. Med. 173:647.
24. Shu, S., R. A. Krinock, T. Matsumura, J. J. Sussman, B. A. Fox, A. E. Chang, and D. S. Terman. 1994. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J. Immunol. 152:1277.
25. Zou, J., N. Yamamoto, T. Fujii, H. Takenaka, M. Kobayashi, S. Hermann, S. Wolf, H. Fujiwara, and T. Hamaoka. 1995. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int. Immunol. 7:1135.
26. Shu, S., T. Chou, and K. Sakai. 1989. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J. Immunol. 143:740.
27. + T cell cultures. Eur J. Immunol. 26:1565.
28. Restifo, N. P., and M. Wang. 1996. Antigen processing and presentation. In Tumor Immunology. A. G. Dalgleish and M. Browning, eds. Cambridge University Press, Cambridge, p. 39.
29. Harding, F. A., J. G. McArthur, J. A. Gross, D. H. Raulet, and J. P. Allison. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607.
30. Linsley, P. S., and J. A. Ledbetter. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11:191.
31. Singh, R., B. Hahn, and E. Sercarz. 1996. Neonatal peptide exposure can prime T cells and, upon subsequent immunization, induce their immune deviation: implications for antibody vs. T cell-mediated autoimmunity. J. Exp. Med. 183:1613.
32. Rocken, M., and E. M. Shevach. 1996. Immune deviation-the third dimension of nondeletional T cell tolerance. Immunol. Rev. 149:175.
33. Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:151.
34. Powrie, F., and R. Coffman. 1993. Cytokine regulation of T-cell function: potential for therapeutic intervention. Immunol. Today 14:270.
35. Afonso, L. C., T. M. Scharton, L. Q. Vieira, M. Wysocka, G. Trinchieri, and P. Scott. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263:235.
36. Heinzel, F. P., R. M. Rerko, F. Ahmed, and E. Pearlman. 1995. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J. Immunol. 155:730.
37. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and M. T. Lotze. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1697.
38. Tahara, H., L. Zitvogel, W. J. Storkus, H. J. R. Zeh, T. G. McKinney. R. D. Schreiber, U. Gubler, P. D. Robbins, and M. T. Lotze. 1995. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154:6466.
39. Rodolfo, M., C. Zilocchi, C. Melani, B. Cappetti, I. Arioli, G. Parmiani, and M. P. Colombo. 1996. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens: comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J Immunol. 157:5536.
40. + T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. Cell. Immunol. 150:114.
41. Maeurer, M., D. Martin, C. Castelli, E. Elder, G. Leder, W. Storkus, and M. Lotze. 1995. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol. Immunother. 41:111.
42. Rothe, H., A. Faust, U. Schade, R. Kleemann, G. Bosse, T. Hibino, S. Martin, and H. Kolb. 1994. Cyclophosphamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-y, but not of interleukin-4. Diabetologia 37:1154.
43. + T cells. J. Exp. Med. 185:461.
44. Wahl, W. L., G. E. Plautz, B. A. Fox, G. J. Nabel, S. Shu, and A. E. Chang. 1992. Generation of therapeutic T lymphocytes after in vivo transfection of a tumor with a gene encoding allogeneic class I major histocompatability complex antigen. Surg. Forum 43:476.
45. Wahl, W., S. Strome, G. Nabel, G. Plautz, M. Cameron, H. San, B. Fox, S. Shu, and A. E. Chang. 1995. Generation of therapeutic T-lymphocytes after in vivo tumor transfection with an allogeneic class I major histocompatibility complex gene. J. Immunother. 17:1-11.
46. Plautz, G. E., Z. Y. Yang, B. Y. Wu, X. Gao, L. Huang, and G. J. Nabel. 1993. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. USA 90:4645.
47. Bach, F. H., C. Ferran, P. Hechenleitner, W. Mark, N. Koyamada, T. Miyatake, H. Winkler, A. Badrichani, D. Candinas, and W. W. Hancock. 1997. Accommodation of vascularized xenografts: expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environment. Nat. Med. 3:196.
48. + T cells. J. Exp. Med. 182:1591.
49. + T helper cell phenotype development in a T cell receptor-αβ-transgenic model. J. Exp. Med. 182:1579.
50. Fox, B. A., M. Drury, H.-M. Hu, Z. Cao, E. G. Huntzicker, W. Qie, and W. J. Urba. 1998. Lipofection indirectly increases expression of endogenous MHC class I molecules on tumor cells. Cancer Gene Ther. In press.
51. Tough, D. F., S. Sun, and J. Sprent. 1997. T cell stimulation in vivo by lipopolysaccharide (LPS). J. Exp. Med. 185:2089.
52. Halpern, M. D., R. J. Kurlander, and D. S. Pisetsky. 1996. Bacterial DNA induces murine interferon-γ production by stimulation of interleukin-12 and tumor necrosis factor-α. Cell. Immunol. 167:72.
53. Pisetsky, D. I. 1996. Immune activation by bacterial DNA: a new genetic code. Immunity 5:303.
54. Mocci, S., and R. A. Coffman. 1997. The mechanism of in vitro T helper cell type 1 to T helper cell type 2 switching in highly polarized Leishmania major-specific T cell populations. J. Immunol. 158:1559.